Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.51 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.51 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | RRM1 | P23921 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11772104 | 0.94 | DNM1 (0.48) | DNM1MEN1KMT2AALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL9110434 | 0.92 | DNM1 (0.50) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL1721427 | 0.92 | DNM1 (0.44) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL3446652 | 0.89 | EPHX1 (0.46) | DNM1ALDH1A1TSHREPHX1 | |
| SCHEMBL11775651 | 0.88 | RRM1 (0.49) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL8166834 | 0.88 | RRM1 (0.49) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL6658508 | 0.85 | DNM1 (0.40) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL11774595 | 0.85 | DNM1 (0.40) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL31090410 | 0.84 | DNM1 (0.52) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL10879906 | 0.83 | CA12 (0.54) | MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734507-B1 | PROCESS FOR THE SYNTHESIS OF N-SUBSTITUTED CYCLIC ALKYLENE UREAS | ALLNEX IP S À R L (LU) | 2017-05-31 | — | — | EP | claimed |
| US-9440928-B2 | Process for the synthesis of N-substituted cyclic alkylene ureas | Allnex IP S.ar.L. (LU) | 2016-09-13 | — | — | US | claimed |
| US-20140179931-A1 | Process for the Synthesis of N-Substituted Cyclic Alkylene Ureas | ALLNEX USA INC. (US) | 2014-06-26 | — | — | US | claimed |
| EP-2548869-A1 | Process for the Synthesis of N-substituted Cyclic Alkylene Ureas | Cytec Technology Corp. (US) | 2013-01-23 | — | — | EP | claimed |
| EP-2734507-B1 | PROCESS FOR THE SYNTHESIS OF N-SUBSTITUTED CYCLIC ALKYLENE UREAS | ALLNEX IP S À R L (LU) | 2017-05-31 | — | — | EP | disclosed |
| US-9440928-B2 | Process for the synthesis of N-substituted cyclic alkylene ureas | Allnex IP S.ar.L. (LU) | 2016-09-13 | — | — | US | disclosed |
| US-20140179931-A1 | Process for the Synthesis of N-Substituted Cyclic Alkylene Ureas | ALLNEX USA INC. (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2548869-A1 | Process for the Synthesis of N-substituted Cyclic Alkylene Ureas | Cytec Technology Corp. (US) | 2013-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179931-A1 | Process for the Synthesis of N-Substituted Cyclic Alkylene Ureas | CA4, CA2, CDYL | DNM1 3537/4885MEN1 1827/4885KMT2A 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.